Stock Taper 
| DATE | TYPE | RATIO |
|---|---|---|
| 2026-06-24 | Reverse | 1:21 |
Autonomix Medical, Inc., founded in 2014 in The Woodlands, Texas, develops microchip-enabled catheter sensing arrays to detect and treat peripheral nervous system disorders.
A pioneering catheter-based platform utilizing proprietary microchip sensors for precision-guided treatment of peripheral nervous system diseases, currently in clinical development for transvascular RF ablation to alleviate severe pancreatic cance...
On November 17, 2025, Autonomix Medical announced highly positive results from a post-hoc analysis of its first-in-human proof-of-concept study for its transvascular nerve ablation technology for treating severe pancreatic cancer pain. The news, highlighting sustained and clinically meaningful quality-of-life gains for patients, triggered a massive surge in the company's stock price and significant interest from the investment community.
In 2025, Autonomix Medical's leadership initiated a significant strategic shift to evolve from a company focused on a single indication—pancreatic cancer pain—to a multi-indication platform company. This decision leverages their core nerve-sensing and ablation technology to target additional visceral cancers and explore future applications in cardiovascular, pulmonary, and chronic pain management.
Patent expands protection for catheter-based technologies enabling transvascular access, treatment guidance, adaptive treatment delivery, and real-time procedural validation beyond the lumen wall
Overall rating: C+
| PEER | PRICE | |
|---|---|---|
 MOVE | $9.73 | COMPARE |
 HSCS | $3.20 | COMPARE |
 KALA | $0.29 | COMPARE |
 BBLG | $0.47 | COMPARE |
